Shares of Cytosorbents Corp. (CTSO) are soaring over 35% in pre-market today, after the company announced that CytoSorb is now specifically recommended in the Italy Brescia Renal COVID Task Force Guidelines to treat patients with severe COVID-19 infection and Stage 3 renal failure on continuous renal replacement therapy (CRRT), published last week on the Italian Society of Nephrology website.
Chief Executive Officer, Dr. Phillip Chan, stated, “”We are witnessing an acceleration of the COVID-19 pandemic as the total number of infected patients has surpassed 420,000 in 197 countries around the world… As the pandemic worsens, the use of CytoSorb in patients infected with COVID-19 has now begun. CytoSorb has now been used in more than 70 COVID-19 patients to help treat cytokine storm and life-threatening complications such as acute respiratory distress syndrome (ARDS) and shock in Italy, China, Germany, and France…”
Dr. Chan added that the initial positive results seen with the use of CytoSorb are very encouraging, particularly reversal of shock, improved lung function, and weaning from mechanical ventilation. To meet the growing demand for CytoSorb worldwide, the company noted that its manufacturing facility is currently running 24 hours a day, seven days a week.
CytoSorb is approved in the European Union and distributed in 58 countries around the world. CytoSorb is not yet approved in the United States.
Source: Read Full Article